The PPAR-delta pathway in neural function and Huntington's disease neuropathology
Funded Grant
Overview
Affiliation
View All
Overview
description
DESCRIPTION (provided by applicant): Huntington's disease (HD) is a relentlessly progressive autosomal dominant neurodegenerative disorder characterized by involuntary movements and cognitive decline. HD results from a CAG trinucleotide repeat expansion in the coding region of the huntingtin (htt) gene, and pathogenesis stems from production of htt protein with an expanded polyglutamine tract. We found that the mitochondrial dysfunction and metabolic deficits in HD result from transcriptional dysregulation of peroxisome proliferator-activated receptor [PPAR] gamma coactivator-1 alpha (PGC-To determine the basis for PGC transcription interference in HD, we performed an unbiased screen for htt-interacting protins, and identified PPARs as candidate interactors. When we evaluated the different PPARs, we documented a physical interaction between PPAR and htt in the cortex of BAC-HD97 transgenic mice, and confirmed that PPAR is highly expressed in neurons. Mutant htt repressed PPAR transactivation in neurons from BAC-HD97 mice, but could be rescued by PPAR agonist treatment or over-expression. These findings formed the basis for our initial R01 project where we proposed to determine the role of the PPAR-PGC-1 pathway in HD pathogenesis, define the function of PPAR in the CNS, and test if PPAR agonist therapy might be a viable treatment paradigm for HD and related disorders. In the last funding cycle, we confirmed the importance of the PPAR-PGC-1 pathway in HD by documenting that htt physically interacts with PPAR and represses PPAR transactivation function to yield mitochondrial dysfunction and neurotoxicity, and determined that transgenic mice expressing dominant-negative PPAR in the striatum recapitulate HD-like phenotypes. Furthermore, we observed neurological disease phenotypes in mice expressing dominant-negative PPAR, thereby identifying neurons as a cell type where PPAR function is essential for homeostasis. Finally, we validated a selective and potent PPAR agonist, KD3010, as capable of rescuing htt neurotoxicity, and performed a preclinical trial of KD3010 in HD mice, where we documented significant improvements in motor function, neurodegeneration, and survival. In this renewal proposal, we will determine how PPAR promotes neuroprotection by examining the effects of PPAR on bioenergetics function, autophagy, and mitochondrial quality control. We will determine how PPAR counters htt neurotoxicity by defining the cistrome and active regulome of PPAR in normal neurons and HD neurons, and we will seek the basis for PPAR neuroprotection by transcriptome analysis of HD mice treated with PPAR agonist to identify genes and pathways required for PPAR neuroprotection. To evaluate the contribution of such genes and pathways to PPAR neuroprotection, we will test if expression modulation of target genes is sufficient to produce rescue in BAC-HD and HD patient neurons, or is capable of preventing rescue by PPAR agonists.
